Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -14,851 | -10,256 | -4,478 | -18,054 | -13,775 |
| Depreciation Amortization | 171 | 164 | 5 | 7 | 2 |
| Accounts receivable | 40 | -40 | -25 | 70 | 96 |
| Accounts payable and accrued liabilities | -417 | -397 | -192 | 61 | -309 |
| Other Working Capital | -358 | -694 | -1,623 | 171 | -467 |
| Other Operating Activity | 772 | 685 | 340 | 394 | 658 |
| Operating Cash Flow | $-14,643 | $-10,538 | $-5,972 | $-17,351 | $-13,795 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 13,787 | -3,275 | -5,839 | -15,763 | -20,726 |
| PPE Investments | -14 | -14 | N/A | -243 | -243 |
| Investing Cash Flow | $13,772 | $-3,289 | $-5,839 | $-16,006 | $-20,969 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -249 | -249 |
| Common Stock Issued | 8,543 | 8,543 | 8,579 | 44 | 44 |
| Financing Cash Flow | $8,543 | $8,543 | $8,579 | $-205 | $-205 |
| Beginning Cash Position | 7,189 | 7,189 | 7,189 | 40,750 | 40,750 |
| End Cash Position | 14,861 | 1,905 | 3,957 | 7,189 | 5,782 |
| Net Cash Flow | $7,673 | $-5,283 | $-3,232 | $-33,562 | $-34,968 |
| Free Cash Flow | |||||
| Operating Cash Flow | -14,643 | -10,538 | -5,972 | -17,351 | -13,795 |
| Capital Expenditure | -14 | -14 | N/A | -243 | -243 |
| Free Cash Flow | -14,657 | -10,552 | -5,972 | -17,594 | -14,038 |